A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
2012 · Investigational New Drugs · 35 citations
https://doi.org/10.1007/s10637-012-9802-1